TTRX · Turn Therapeutics Inc. · Executive Compensation
$13.16
+0.47 (+3.68%)
At close · Sep 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$378.01M
Shares
29.79M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Martin Dewhurst | independent Class III director | Appointed | 2026-01-07 |
| Dr. Kent Kester | director | Appointed | 2025-10-02 |
| Arthur Golden | director | Appointed | 2025-10-02 |